Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells

被引:21
|
作者
deFabritiis, P
Skorski, T
DePropris, MS
Paggi, MG
NieborowskaSkorska, M
Lisci, A
Buffolino, S
Campbell, K
Geiser, T
Calabretta, B
机构
[1] REGINA ELENA INST CANC RES,I-00161 ROME,ITALY
[2] THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107
[3] LYNX THERAPEUT,HAYWARD,CA
关键词
bcr-abl oligonucleotides; p210(bcr-abl); chronic myelogenous leukaemia; CD34(+) cells;
D O I
10.1038/sj.leu.2400664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We studied the effect of phosphorothioate oligodeoxynucleotides ([S]ODNs) complementary to the bcr-abl junction on cells taken at diagnosis from 41 patients with Philadelphia-positive chronic myelogenous leukaemia (CML). Experiments included the evaluation of the anti-leukaemic effect of 16- and 26-mer antisense [S]ODNs on both mononuclear and CD34(+) cells, evaluation of incubation time and correlation of colony growth inhibition with the down-regulation of p210(bcr-abl). At the same time, the uptake of [S]ODNs by mononuclear and purified CD34(+) cell populations and the cross-hybridization of 26- and 16-mer [S]ODNs with the complementary sequences were evaluated. After incubation for 120 h with 26-mer antisense [S]ODNs on mononuclear cells, overall mean colony recovery was 41.9% of the untreated control samples; in particular, a significant reduction in colony formation was observed in 22 of the 35 cases tested. The effect of 26-mer ODNs on CD34(+) cells was comparable to that observed on mononuclear cells in terms of colony inhibition; however, a higher proportion of cases showed a significant inhibition of colony formation. In comparison with the 26-mer antisense [S]ODNs, the anti-leukaemic effect of the 16-mer antisense [S]ODNs was less evident on mononuclear cells and comparable on CD34(+) cells; however, a more specific effect was evident on both target cells. Hybridization experiments confirmed a partial cross-reactivity when the 26-mer ODNs were hybridized with their complementary sequence; this did not occur when 16-mer ODNs were similarly tested. Experiments aimed at evaluating the effect of the incubation time showed a significant increase in anti-leukaemic effect after a 120 h incubation period compared to that measured after a 24 h incubation period; this was parallelled by a progressive increase in the intracellular concentrations of [S]ODNs from day 1 to day 5. The accumulation of [S]ODNs correlated with a marked down-regulation of p210(bcr-abl) levels which was first detectable after 72 h of treatment. The downregulation of p210(bcr-abl) levels following treatment with [S]ODNs showed a correlation between the effect of antisense [S]ODNs on leukaemic colony formation and protein expression. These studies confirm that, under optimal conditions of target cell culture and ODN size, antisense [S]ODNs complementary to the bcr-abl junction have specific anti-leukaemic effects.
引用
收藏
页码:811 / 819
页数:9
相关论文
共 50 条
  • [21] BCR-ABL in chronic myelogenous leukemia - How does it work?
    Goldman, John M.
    Melo, Junia V.
    ACTA HAEMATOLOGICA, 2008, 119 (04) : 212 - 217
  • [22] MOLECULAR CONSEQUENCES OF THE BCR-ABL TRANSLOCATION IN CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    LEUKEMIA & LYMPHOMA, 1993, 11 : 101 - 103
  • [23] BCR-ABL fusion gene and BCR-ABL transcript -: Correlation with response to therapy in Chronic Myeloid Leukaemia.
    Geraldes, C
    Gonçalves, AC
    Santos, P
    Tavares, P
    Teixeira, A
    BLOOD, 2005, 106 (11) : 297B - 297B
  • [24] A novel BCR-ABL rearrangement in a Philadelphia chromosome-positive chronic myelogenous leukaemia variant with thrombocythaemia
    Rubinstein, R
    Purves, LR
    LEUKEMIA, 1998, 12 (02) : 230 - 232
  • [25] Can p230(BCR-ABL) myeloproliferative neoplasm be distinguished from chronic myelogenous leukaemia?
    Mayeur-Rousse, Caroline
    Aumerle, Laureen
    Sorel, Nathalie
    Chomel, Jean-Claude
    Turhan, Ali G.
    HEMATOLOGIE, 2009, 15 (06): : 416 - 423
  • [26] A novel BCR-ABL rearrangement in a Philadelphia chromosome-positive chronic myelogenous leukaemia variant with thrombocythaemia
    R Rubinstein
    LR Purves
    Leukemia, 1998, 12 : 230 - 232
  • [27] Induction of BCR-ABL mutations for acquired resistance in chronic myelogenous leukemia cells by imatinib
    Yuan, Hongfeng
    Gao, Chunggang
    Bhatia, Ravi
    Chen, WenYong
    CANCER RESEARCH, 2009, 69
  • [28] A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia
    Jackson, Robert C.
    Radivoyevitch, Tomas
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 765 - 776
  • [29] BCR-ABL peptide immunisation in chronic myeloid leukaemia (CML)
    Clark, RE
    Knight, K
    Wang, L
    Rojas, JM
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 54 - 54
  • [30] CCN3 reduces clonogenic capacity of BCR-ABL cells
    McCallum, L.
    Lu, W.
    Price, S.
    Planque, N.
    Perbal, B.
    Whetton, A. D.
    Irvine, A. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 197 - 198